Publications & Reports

Mannan-mediated gene delivery for cancer immunotherapy.

Tang CK, Lodding J, Minigo G, Pouniotis DS, Plebanski M, Scholzen A, McKenzie IF, Pietersz GA, Apostolopoulos V
Immunology and Vaccine Laboratory, Burnet Institute at Austin, Heidelberg, VIC, Australia.


Recent years have seen a resurgence in interest in the development of efficient non-viral delivery systems for DNA vaccines and gene therapy. We have previously used oxidized and reduced mannan as carriers for protein delivery to antigen-presenting cells by targeting the receptors that bind mannose, resulting in efficient induction of cellular responses. In the present study, oxidized mannan and reduced mannan were used as receptor-mediated gene transfer ligands for cancer immunotherapy. In vivo studies in C57BL/6 mice showed that injection of DNA encoding ovalbumin (OVA) complexed to oxidized or reduced mannan-poly-L-lysine induced CD8 and CD4 T-cell responses as well as antibody responses leading to protection of mice from OVA+ tumours. Both oxidized and reduced mannan delivery was superior to DNA alone or DNA-poly-L-lysine. These studies demonstrate the potential of oxidized and reduced mannan for efficient receptor-mediated gene delivery in vivo, particularly as DNA vaccines for cancer immunotherapy.


  • Journal: Immunology
  • Published: 01/03/2007
  • Volume: 120
  • Issue: 3
  • Pagination: 325-335